Combination of an antigen-specific therapy and an immunomodulatory treatment to simultaneous block recurrent autoimmunity and alloreactivity in non-obese diabetic mice

PLoS ONE

Volumn 10, Issue 6, 2015, Pages

  Fousteri, Georgia ^a   Jofra, Tatiana ^a   Di Fonte, Roberta ^a   Battaglia, Manuela ^a  

^a SAN RAFFAELE HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

EPITOPE; FREUND ADJUVANT; GLUCOSE 6 PHOSPHATASE; GLUTAMATE DECARBOXYLASE 65; GLUTAMATE DECARBOXYLASE 65 PEPTIDE[524-543]; INSULIN; INSULIN B CHAIN PEPTIDE[9-23]; INTERLEUKIN 10; ISLET SPECIFIC GLUCOSE 6 PHOSPHATASE CATALYTIC SUBUNIT RELATED PROTEIN PEPTIDE[206-214]; LENOGRASTIM; RAPAMYCIN; UNCLASSIFIED DRUG; GRANULOCYTE COLONY STIMULATING FACTOR; IMMUNOSUPPRESSIVE AGENT;

ALLOIMMUNITY; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTOIMMUNITY; CD4+ CD25+ T LYMPHOCYTE; CONTROLLED STUDY; CYTOKINE PRODUCTION; ENGRAFTMENT; FEMALE; GRAFT REJECTION; GRAFT SURVIVAL; INSULIN DEPENDENT DIABETES MELLITUS; MOUSE; NONHUMAN; NONOBESE DIABETIC MOUSE; PANCREAS ISLET TRANSPLANTATION; REGULATORY T LYMPHOCYTE; TRANSPLANTATION TOLERANCE; ANIMAL; BAGG ALBINO MOUSE; DRUG EFFECTS; IMMUNIZATION; IMMUNOLOGY; IMMUNOMODULATION; IMMUNOTHERAPY; PROCEDURES;

MUS;

ANIMALS; AUTOIMMUNITY; GRAFT REJECTION; GRANULOCYTE COLONY-STIMULATING FACTOR; IMMUNIZATION; IMMUNOMODULATION; IMMUNOSUPPRESSIVE AGENTS; IMMUNOTHERAPY; ISLETS OF LANGERHANS TRANSPLANTATION; MICE, INBRED BALB C; MICE, INBRED NOD; SIROLIMUS;

EID: 84937861505     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0127631     Document Type: Article

References (47)

1. van Belle TL, Coppieters KT, von Herrath MG. Type 1 diabetes: etiology, immunology, and therapeutic strategies. Physiol Rev. 2011; 91(1):79-118. Epub 2011/01/21. doi: 10.1152/physrev.00003.2010 91/ 1/79 [pii]. PMID: 21248163.
2. Bluestone JA, Herold K, Eisenbarth G. Genetics, pathogenesis and clinical interventions in type 1 diabetes. Nature. 2010; 464(7293):1293-300. Epub 2010/05/01. PMID: 20432533.
3. Roep BO, Peakman M. Antigen targets of type 1 diabetes autoimmunity. Cold Spring Harb Perspect Med. 2012; 2(4):a007781. Epub 2012/04/05. doi: 10.1101/cshperspect.a007781 a007781 [pii]. PMID: 22474615; PubMed Central PMCID: PMC3312399.
4. Shoda LK, Young DL, Ramanujan S, Whiting CC, AtkinsonMA, Bluestone JA, et al. A comprehensive review of interventions in the NOD mouse and implications for translation. Immunity. 2005; 23(2):115-26. Epub 2005/08/23. S1074-7613(05)00240-2 [pii] doi: 10.1016/j.immuni.2005.08.002 PMID: 16111631.
5. Fousteri G, Bresson D, von Herrath M. Rational development of antigen-specific therapies for type 1 diabetes. Adv Exp Med Biol. 2007; 601:313-9. Epub 2007/08/24. PMID: 17713020.
6. Ryden AK, Wesley JD, Coppieters KT, Von Herrath MG. Non-antigenic and antigenic interventions in type 1 diabetes. Hum Vaccin Immunother. 2014; 10(4):838-46. Epub 2013/10/30. 26890 [pii]. PMID: 24165565.
7. Bresson D, von Herrath M. Immunotherapy for the prevention and treatment of type 1 diabetes: optimizing the path from bench to bedside. Diabetes Care. 2009; 32(10):1753-68. Epub 2009/10/02. doi: 10. 2337/dc09-0373 32/10/1753 [pii]. PMID: 19794001; PubMed Central PMCID: PMC2752914.
8. Coppieters KT, Harrison LC, von Herrath MG. Trials in type 1 diabetes: Antigen-specific therapies. Clin Immunol. 2013; 149(3):345-55. Epub 2013/03/16. doi: 10.1016/j.clim.2013.02.002 S1521-6616(13) 00028-4 [pii]. PMID: 23490422.
9. Peakman M, von Herrath M. Antigen-specific immunotherapy for type 1 diabetes: maximizing the potential. Diabetes. 2010; 59(9):2087-93. Epub 2010/09/02. doi: 10.2337/db10-0630 59/9/2087 [pii]. PMID: 20805382; PubMed Central PMCID: PMC2927927.
10. Ramesh A, Chhabra P, Brayman KL. Pancreatic islet transplantation in type 1 diabetes mellitus: an update on recent developments. Curr Diabetes Rev. 2013; 9(4):294-311. Epub 2013/06/01. CDR-EPUB- 20130531-1 [pii]. PMID: 23721158.
11. Kimelman M, Brandacher G. Trends in immunosuppression after pancreas transplantation: what is in the pipeline? Curr Opin Organ Transplant. 2013; 18(1):76-82. Epub 2012/12/21. doi: 10.1097/MOT. 0b013e32835c6eda PMID: 23254700.
12. Gruessner RW, Gruessner AC. The current state of pancreas transplantation. Nat Rev Endocrinol. 2013; 9(9):555-62. Epub 2013/07/31. doi: 10.1038/nrendo.2013.138 nrendo.2013.138 [pii]. PMID: 23897173.
13. Chujo D, Foucat E, Takita M, Itoh T, Sugimoto K, Shimoda M, et al. Emergence of a broad repertoire of GAD65-specific T-cells in type 1 diabetes patients with graft dysfunction after allogeneic islet transplantation. Cell Transplant. 2012; 21(12):2783-95. Epub 2012/09/12. doi: 10.3727/096368912X654993 ct0655chujo [pii]. PMID: 22963904.
14. Abreu JR, Roep BO. Immune monitoring of islet and pancreas transplant recipients. Curr Diab Rep. 2013; 13(5):704-12. Epub 2013/08/15. doi: 10.1007/s11892-013-0399-3 PMID: 23943207.
15. Stegall MD, Lafferty KJ, Kam I, Gill RG. Evidence of recurrent autoimmunity in human allogeneic islet transplantation. Transplantation. 1996; 61(8):1272-4. Epub 1996/04/27. PMID: 8610431.
16. Laughlin E, Burke G, Pugliese A, Falk B, Nepom G. Recurrence of autoreactive antigen-specific CD4+ T cells in autoimmune diabetes after pancreas transplantation. Clin Immunol. 2008; 128(1):23-30. Epub 2008/05/06. doi: 10.1016/j.clim.2008.03.459 S1521-6616(08)00524-X [pii]. PMID: 18455963; PubMed Central PMCID: PMC2531116.
17. Monti P, Scirpoli M, Maffi P, Ghidoli N, De Taddeo F, Bertuzzi F, et al. Islet transplantation in patients with autoimmune diabetes induces homeostatic cytokines that expand autoreactive memory T cells. J Clin Invest. 2008; 118(5):1806-14. Epub 2008/04/24. doi: 10.1172/JCI35197 PMID: 18431516; PubMed Central PMCID: PMC2323193.
18. Burke GW 3rd, Vendrame F, Pileggi A, Ciancio G, Reijonen H, Pugliese A. Recurrence of autoimmunity following pancreas transplantation. Curr Diab Rep. 2011; 11(5):413-9. Epub 2011/06/11. doi: 10.1007/ s11892-011-0206-y PMID: 21660419; PubMed Central PMCID: PMC4018301.
19. Vendrame F, Pileggi A, Laughlin E, Allende G, Martin-Pagola A, Molano RD, et al. Recurrence of type 1 diabetes after simultaneous pancreas-kidney transplantation, despite immunosuppression, is associated with autoantibodies and pathogenic autoreactive CD4 T-cells. Diabetes. 2010; 59(4):947-57. Epub 2010/ 01/21. doi: 10.2337/db09-0498 db09-0498 [pii]. PMID: 20086230; PubMed Central PMCID: PMC2844842.
20. Shapiro AM. Islet transplantation in type 1 diabetes: ongoing challenges, refined procedures, and longterm outcome. Rev Diabet Stud. 2012; 9(4):385-406. Epub 2012/01/01. doi: 10.1900/RDS.2012.9.385 PMID: 23804275; PubMed Central PMCID: PMC3740705.
21. van de Linde P, Roep BO. T-cell assays to determine disease activity and clinical efficacy of immune therapy in type 1 diabetes. Am J Ther. 2005; 12(6):573-9. Epub 2005/11/11. 00045391-200511000-00014 [pii]. PMID: 16280651.
22. Pearson T, Markees TG, Serreze DV, Pierce MA, Wicker LS, Peterson LB, et al. Islet cell autoimmunity and transplantation tolerance: two distinct mechanisms? Ann N Y Acad Sci. 2003; 1005:148-56. Epub 2003/12/18. PMID: 14679049.
23. Fousteri G, Dave A, Bot A, Juntti T, Omid S, von Herrath M. Subcutaneous insulin B:9-23/IFA immunisation induces Tregs that control late-stage prediabetes in NOD mice through IL-10 and IFNgamma. Diabetologia. 2010; 53(9):1958-70. Epub 2010/05/22. doi: 10.1007/s00125-010-1777-x PMID: 20490452; PubMed Central PMCID: PMC2910887.
24. Fousteri G, Chan JR, Zheng Y, Whiting C, Dave A, Bresson D, et al. Virtual optimization of nasal insulin therapy predicts immunization frequency to be crucial for diabetes protection. Diabetes. 2010; 59 (12):3148-58. Epub 2010/09/25. doi: 10.2337/db10-0561 db10-0561 [pii]. PMID: 20864513; PubMed Central PMCID: PMC2992777.
25. Tian J, Clare-Salzler M, Herschenfeld A, Middleton B, Newman D, Mueller R, et al. Modulating autoimmune responses to GAD inhibits disease progression and prolongs islet graft survival in diabetesprone mice. Nat Med. 1996; 2(12):1348-53. Epub 1996/12/01. PMID: 8946834.
26. Rayat GR, Singh B, Korbutt GS, Rajotte RV. Single injection of insulin delays the recurrence of diabetes in syngeneic islet-transplanted diabetic NOD mice. Transplantation. 2000; 70(6):976-9. Epub 2000/10/03. PMID: 11014652.
27. Ravanan R, Wong SF, Morgan NG, Mathieson PW, Smith RM. Inhalation of glutamic acid decarboxylase 65-derived peptides can protect against recurrent autoimmune but not alloimmune responses in the non-obese diabetic mouse. Clin Exp Immunol. 2007; 148(2):368-72. Epub 2007/04/18. CEI3358 [pii] doi: 10.1111/j.1365-2249.2007.03358.x PMID: 17437424; PubMed Central PMCID: PMC1868866.
28. Kirk AD. Induction immunosuppression. Transplantation. 2006; 82(5):593-602. Epub 2006/09/14. doi: 10.1097/01.tp.0000234905.56926.7f 00007890-200609150-00001 [pii]. PMID: 16969280.
29. Larsen CP, Knechtle SJ, Adams A, Pearson T, Kirk AD. A new look at blockade of T-cell costimulation: a therapeutic strategy for long-term maintenance immunosuppression. Am J Transplant. 2006; 6(5 Pt 1):876-83. Epub 2006/04/14. AJT1259 [pii] doi: 10.1111/j.1600-6143.2006.01259.x PMID: 16611323.
30. Stratta RJ, Farney AC, Rogers J, Orlando G. Immunosuppression for pancreas transplantation with an emphasis on antibody induction strategies: review and perspective. Expert Rev Clin Immunol. 2014; 10 (1):117-32. Epub 2013/11/19. doi: 10.1586/1744666X.2014.853616 PMID: 24236648.
31. Markees TG, Serreze DV, Phillips NE, Sorli CH, Gordon EJ, Shultz LD, et al. NOD mice have a generalized defect in their response to transplantation tolerance induction. Diabetes. 1999; 48(5):967-74. Epub 1999/05/20. PMID: 10331399.
32. Rossini AA, Mordes JP, Greiner DL, Stoff JS. Islet cell transplantation tolerance. Transplantation. 2001; 72(8 Suppl):S43-6. Epub 2002/03/13. PMID: 11888156.
33. Pearson T, Markees TG, Wicker LS, Serreze DV, Peterson LB, Mordes JP, et al. NOD congenic mice genetically protected from autoimmune diabetes remain resistant to transplantation tolerance induction. Diabetes. 2003; 52(2):321-6. Epub 2003/01/24. PMID: 12540603.
34. Molano RD, Berney T, Li H, Cattan P, Pileggi A, Vizzardelli C, et al. Prolonged islet graft survival in NOD mice by blockade of the CD40-CD154 pathway of T-cell costimulation. Diabetes. 2001; 50 (2):270-6. Epub 2001/03/29. PMID: 11272136.
35. Makhlouf L, Kishimoto K, Smith RN, Abdi R, Koulmanda M, Winn HJ, et al. The role of autoimmunity in islet allograft destruction: major histocompatibility complex class II matching is necessary for autoimmune destruction of allogeneic islet transplants after T-cell costimulatory blockade. Diabetes. 2002; 51 (11):3202-10. Epub 2002/10/29. PMID: 12401711.
36. Gagliani N, Gregori S, Jofra T, Valle A, Stabilini A, Rothstein DM, et al. Rapamycin combined with anti- CD45RB mAb and IL-10 or with G-CSF induces tolerance in a stringent mouse model of islet transplantation. PLoS One. 2011; 6(12):e28434. Epub 2011/12/17. doi: 10.1371/journal.pone.0028434 PONED- 11-10896 [pii]. PMID: 22174806; PubMed Central PMCID: PMC3235119.
37. Gagliani N, Jofra T, Valle A, Stabilini A, Morsiani C, Gregori S, et al. Transplant tolerance to pancreatic islets is initiated in the graft and sustained in the spleen. Am J Transplant. 2013; 13(8):1963-75. Epub 2013/07/10. doi: 10.1111/ajt.12333 PMID: 23834659; PubMed Central PMCID: PMC3869180.
38. Fousteri G, Dave A, Juntti T, von Herrath M. CD103 is dispensable for anti-viral immunity and autoimmunity in a mouse model of virally-induced autoimmune diabetes. J Autoimmun. 2009; 32(1):70-7. Epub 2009/01/24. doi: 10.1016/j.jaut.2008.12.001 S0896-8411(08)00137-6 [pii]. PMID: 19162441; PubMed Central PMCID: PMC2706207.
39. Setiady YY, Coccia JA, Park PU. In vivo depletion of CD4+FOXP3+ Treg cells by the PC61 anti-CD25 monoclonal antibody is mediated by FcgammaRIII+ phagocytes. Eur J Immunol. 2010; 40(3):780-6. Epub 2009/12/30. doi: 10.1002/eji.200939613 PMID: 20039297.
40. Orlando G, Gianello P, Salvatori M, Stratta RJ, Soker S, Ricordi C, et al. Cell replacement strategies aimed at reconstitution of the beta-cell compartment in type 1 diabetes. Diabetes. 2014; 63(5):1433-44. Epub 2014/04/24. doi: 10.2337/db13-1742 63/5/1433 [pii]. PMID: 24757193.
41. Han B, Serra P, Amrani A, Yamanouchi J, Maree AF, Edelstein-Keshet L, et al. Prevention of diabetes by manipulation of anti-IGRP autoimmunity: high efficiency of a low-affinity peptide. Nat Med. 2005; 11 (6):645-52. Epub 2005/05/24. nm1250 [pii] doi: 10.1038/nm1250 PMID: 15908957.
42. Krishnamurthy B, Dudek NL, McKenzie MD, Purcell AW, Brooks AG, Gellert S, et al. Responses against islet antigens in NOD mice are prevented by tolerance to proinsulin but not IGRP. J Clin Invest. 2006; 116(12):3258-65. Epub 2006/12/05. doi: 10.1172/JCI29602 PMID: 17143333; PubMed Central PMCID: PMC1679712.
43. Olcott AP, Tian J, Walker V, Dang H, Middleton B, Adorini L, et al. Antigen-based therapies using ignored determinants of beta cell antigens can more effectively inhibit late-stage autoimmune disease in diabetes- prone mice. J Immunol. 2005; 175(3):1991-9. Epub 2005/07/22. 175/3/1991 [pii]. PMID: 16034144.
44. Tian J, Atkinson MA, Clare-Salzler M, Herschenfeld A, Forsthuber T, Lehmann PV, et al. Nasal administration of glutamate decarboxylase (GAD65) peptides induces Th2 responses and prevents murine insulin- dependent diabetes. J Exp Med. 1996; 183(4):1561-7. Epub 1996/04/01. PMID: 8666914; PubMed Central PMCID: PMC2192503.
45. Yoon JW, Yoon CS, Lim HW, Huang QQ, Kang Y, Pyun KH, et al. Control of autoimmune diabetes in NOD mice by GAD expression or suppression in beta cells. Science. 1999; 284(5417):1183-7. Epub 1999/05/15. PMID: 10325232.
46. Lutterotti A, Yousef S, Sputtek A, Sturner KH, Stellmann JP, Breiden P, et al. Antigen-specific tolerance by autologous myelin peptide-coupled cells: a phase 1 trial in multiple sclerosis. Sci Transl Med. 2013; 5(188):188ra75. Epub 2013/06/07. doi: 10.1126/scitranslmed.3006168 5/188/188ra75 [pii]. PMID: 23740901; PubMed Central PMCID: PMC3973034.
47. Tian J, Olcott AP, Kaufman DL. Antigen-based immunotherapy drives the precocious development of autoimmunity. J Immunol. 2002; 169(11):6564-9. Epub 2002/11/22. PMID: 12444168.